Valuation: Alvotech

Market Cap 209.86Cr 184.16Cr 173.93Cr 158.5Cr 296.71Cr 20TCr 298.83Cr 2.08TCr 806.13Cr 10TCr 787.96Cr 770.92Cr 33TCr P/E 2026 *
113x
P/E 2027 * 19.8x
Enterprise Value 317.55Cr 278.65Cr 263.17Cr 239.83Cr 448.96Cr 30TCr 452.16Cr 3.15TCr 1.22TCr 16TCr 1.19TCr 1.17TCr 50TCr EV / Sales 2026 *
4.82x
EV / Sales 2027 * 4.07x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day-0.94%
Current month-37.95%
Current year-37.95%
5 years 5.67
Extreme 5.67
10.44
10 years 5.67
Extreme 5.67
11.62
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
21/09/20 OthersCompany 2,18,750 3.8889%
16/09/20 OtherCompany 0 0% -
16/09/20 OtherCompany 64,68,750 -
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%+10.11% - - 209.86Cr
-0.14%+4.33%+9.88%+31.73% 4.8TCr
-1.31%+2.10%+53.95%+34.40% 4.53TCr
+0.86%+3.40%+10.36%+90.55% 4.09TCr
+3.24%+8.10%+385.58%+599.73% 4.28TCr
-0.62%-1.61%+5.30%+46.02% 2.96TCr
-1.37%+0.08%+25.59%+150.43% 1.73TCr
-0.46%+1.20%+26.78%+41.32% 1.53TCr
-2.43%-4.73% - - 1.52TCr
+3.02%+8.88%+9.65% - 1.48TCr
Average -0.02%+1.02%+65.89%+142.03% 2.99TCr
Weighted average by Cap. +0.24%+1.56%+82.68%+154.94%

Financials

2026 *2027 *
Net sales 66Cr 58Cr 55Cr 50Cr 93Cr 6.32TCr 94Cr 653.88Cr 253.26Cr 3.23TCr 247.55Cr 242.2Cr 10TCr 78Cr 68Cr 64Cr 59Cr 109.67Cr 7.43TCr 110.45Cr 769.28Cr 297.96Cr 3.8TCr 291.24Cr 284.94Cr 12TCr
Net income 3.04Cr 2.66Cr 2.52Cr 2.29Cr 4.29Cr 290.99Cr 4.32Cr 30Cr 12Cr 148.66Cr 11Cr 11Cr 477.78Cr 11Cr 9.57Cr 9.04Cr 8.24Cr 15Cr 1.05TCr 16Cr 108.21Cr 42Cr 534.25Cr 41Cr 40Cr 1.72TCr
Net Debt 107.69Cr 94Cr 89Cr 81Cr 152.25Cr 10TCr 153.34Cr 1.07TCr 413.65Cr 5.27TCr 404.33Cr 395.58Cr 17TCr 105.72Cr 93Cr 88Cr 80Cr 149.46Cr 10TCr 150.53Cr 1.05TCr 406.07Cr 5.18TCr 396.92Cr 388.34Cr 17TCr
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change
25/26/25 $5.820 -1.02%
24/26/24 $5.880 +1.20%
23/26/23 $5.810 -0.51%
22/26/22 $5.840 -0.68%
21/26/21 $5.880 +0.17%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.880USD
Average target price
6.800USD
Spread / Average Target
+15.65%

Quarterly revenue - Rate of surprise